Stoneridge Investment Partners Has Lowered Viacom Class B (VIAB) Holding; 2 Analysts Are Bullish United Therapeutics (UTHR) Last Week

May 20, 2018 - By Ann Lacey

Viacom, Inc. (NASDAQ:VIAB) Logo

Stoneridge Investment Partners Llc decreased Viacom Inc Class B (VIAB) stake by 8.36% reported in 2017Q4 SEC filing. Stoneridge Investment Partners Llc sold 22,799 shares as Viacom Inc Class B (VIAB)’s stock declined 4.65%. The Stoneridge Investment Partners Llc holds 249,938 shares with $7.70M value, down from 272,737 last quarter. Viacom Inc Class B now has $11.19 billion valuation. The stock decreased 3.27% or $0.92 during the last trading session, reaching $27.24. About 5.12 million shares traded or 55.91% up from the average. Viacom, Inc. (NASDAQ:VIAB) has declined 30.65% since May 20, 2017 and is downtrending. It has underperformed by 42.20% the S&P500.

Among 12 analysts covering United Therapeutics (NASDAQ:UTHR), 2 have Buy rating, 3 Sell and 7 Hold. Therefore 17% are positive. United Therapeutics had 35 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was downgraded by Ladenburg Thalmann to “Neutral” on Thursday, February 23. The company was maintained on Tuesday, July 18 by Oppenheimer. Wedbush maintained the stock with “Buy” rating in Wednesday, December 27 report. On Friday, February 26 the stock rating was maintained by Barclays Capital with “Equal-Weight”. The stock of United Therapeutics Corporation (NASDAQ:UTHR) has “Sell” rating given on Sunday, August 13 by Jefferies. The stock has “Underweight” rating by Barclays Capital on Thursday, February 22. The firm earned “Sell” rating on Tuesday, June 6 by Jefferies. The rating was maintained by Cowen & Co with “Hold” on Thursday, July 27. The company was maintained on Thursday, February 22 by Credit Suisse. The company was maintained on Wednesday, July 29 by RBC Capital Markets. See United Therapeutics Corporation (NASDAQ:UTHR) latest ratings:

04/05/2018 Broker: Wedbush Rating: Buy New Target: $234.0000 Maintain
03/05/2018 Broker: Barclays Capital Old Rating: Underweight New Rating: Underweight Old Target: $105 New Target: $95 Maintain
03/05/2018 Broker: Credit Suisse Old Rating: Neutral New Rating: Neutral Old Target: $108 New Target: $104 Maintain
03/04/2018 Broker: Credit Suisse Old Rating: Underperform New Rating: Neutral Old Target: $115 Upgrade
27/02/2018 Broker: Wedbush Rating: Buy New Target: $234.0 Maintain
22/02/2018 Broker: Barclays Capital Old Rating: Underweight New Rating: Underweight Old Target: $115 New Target: $105 Maintain
22/02/2018 Broker: Credit Suisse Old Rating: Underperform New Rating: Underperform Old Target: $120 New Target: $115 Maintain
19/01/2018 Broker: Barclays Capital Rating: Sell New Target: $115.0
04/01/2018 Broker: Wedbush Rating: Buy New Target: $232.0 Maintain
27/12/2017 Broker: Wedbush Rating: Buy New Target: $232.0 Maintain

Analysts await Viacom, Inc. (NASDAQ:VIAB) to report earnings on August, 2. They expect $1.08 EPS, down 7.69% or $0.09 from last year’s $1.17 per share. VIAB’s profit will be $443.50 million for 6.31 P/E if the $1.08 EPS becomes a reality. After $0.92 actual EPS reported by Viacom, Inc. for the previous quarter, Wall Street now forecasts 17.39% EPS growth.

More recent Viacom, Inc. (NASDAQ:VIAB) news were published by: Investorplace.com which released: “Viacom, Inc.’s Earnings Beat Isn’t Reason To Celebrate” on April 25, 2018. Also Nasdaq.com published the news titled: “Why Viacom, Synchronoss Technologies, and DHX Media Slumped Today” on May 14, 2018. Seekingalpha.com‘s news article titled: “Viacom Inc. 2018 Q2 – Results – Earnings Call Slides” with publication date: April 25, 2018 was also an interesting one.

Among 39 analysts covering Viacom Inc. (NASDAQ:VIAB), 13 have Buy rating, 0 Sell and 26 Hold. Therefore 33% are positive. Viacom Inc. had 135 analyst reports since August 7, 2015 according to SRatingsIntel. Barclays Capital maintained Viacom, Inc. (NASDAQ:VIAB) rating on Monday, September 26. Barclays Capital has “Overweight” rating and $46 target. The rating was upgraded by Deutsche Bank to “Hold” on Monday, November 20. The stock has “Hold” rating by Topeka Capital Markets on Wednesday, December 23. The firm has “Hold” rating given on Friday, February 9 by Piper Jaffray. The company was upgraded on Tuesday, September 13 by Brean Capital. On Friday, November 17 the stock rating was maintained by Cowen & Co with “Hold”. The stock of Viacom, Inc. (NASDAQ:VIAB) earned “Buy” rating by Pivotal Research on Friday, November 13. Topeka Capital Markets maintained Viacom, Inc. (NASDAQ:VIAB) on Friday, August 7 with “Hold” rating. The firm earned “Hold” rating on Wednesday, February 24 by Topeka Capital Markets. The rating was downgraded by Barrington on Tuesday, January 2 to “Hold”.

Stoneridge Investment Partners Llc increased Henry Schein Inc (NASDAQ:HSIC) stake by 75,905 shares to 111,083 valued at $7.76M in 2017Q4. It also upped Visa Inc (NYSE:V) stake by 39,521 shares and now owns 76,664 shares. Whirlpool Corp (NYSE:WHR) was raised too.

More notable recent United Therapeutics Corporation (NASDAQ:UTHR) news were published by: 247Wallst.com which released: “Why SteadyMed Shares Are Skyrocketing” on April 30, 2018, also Nasdaq.com with their article: “SteadyMed Provides Corporate Update and Reports First Quarter 2018 Financial Results” published on May 15, 2018, Prnewswire.com published: “Stock Review for Drug Makers Investors — Endo, Ionis Pharma, Novo Nordisk, and United Therapeutics” on April 30, 2018. More interesting news about United Therapeutics Corporation (NASDAQ:UTHR) were released by: Nasdaq.com and their article: “Mid-Morning Market Update: Markets Open Higher; Sprint And T-Mobile To Merge In $26 Billion Deal” published on April 30, 2018 as well as Globenewswire.com‘s news article titled: “Report: Exploring Fundamental Drivers Behind Reliance Steel & Aluminum, Goldman Sachs BDC, IBERIABANK …” with publication date: May 04, 2018.

The stock decreased 1.33% or $1.43 during the last trading session, reaching $106.27. About 288,980 shares traded. United Therapeutics Corporation (NASDAQ:UTHR) has declined 23.69% since May 20, 2017 and is downtrending. It has underperformed by 35.24% the S&P500.

Since March 14, 2018, it had 0 insider purchases, and 10 sales for $26.79 million activity. 43,024 shares were sold by ROTHBLATT MARTINE A, worth $4.78M on Wednesday, March 28.

United Therapeutics Corporation (NASDAQ:UTHR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: